Genmab — September 2024

[E_L]

@lymphomahub
CONGRESS | #SOHO2024 | POSTER
Lorenzo Falchi
@MSKCancerCenter
presents data from the phase I/II EPCORE NHL-2 trial of fixed-duration epcoritamab + R2 in 1L FL (updated data from Arm 6) and single-agent epcoritamab as maintenance treatment after SOC in FL (first disclosure of Arm 7). N=41, ORR=95%,CR=85%. https://x.com/lymphomahub/status/1833200014384107809

[lahn1]

Solsen, tro ikke der er mange der har store forventninger til Rybrevant i1L selvomeSC Rybrevant havde en brdre AE profil. Men JNJ sigter vel stadigvæk efter 50% mrk shr i 1 L og det er optimistisk.

[lahn1]

Selvom PFS peger på en fordel til Tagrisso så mangler vi OS data for begge.

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[bibob]

God morgen.

[transalp]

Go morgen ..

[LP90]

Godmorgen

[E_L]

it is going to be hard to keep track of all the data releases for Epcoritamab... all the different arms... let alone the comparison with competition...

[E_L]

then again, with ORRs of 95% and CRs of 85%, maybe you don't really need comparisons anymore

[E_L]

Xencor yesterday announced they plan to start a trial with their CD3xCD20 in autoimmune diseases by the way... (this is the asset they had in development with JNJ for blood cancers, but where JNJ opted out...)

[lahn1]

You doing a great job EL many thx for all your links.

[E_L]

would be nice if one day one of those links would lead to a positive price move for a change lol

[lahn1]

Your lates on Epco should!!, looks like best in class !

[lahn1]

Wonder, if data holds up, if they are good enough for an accelerate approval down the line.

[Hugininvest]

Måske nogen er ved at komme til fornuft
i dag

[Hugininvest]

Selv uden yderligere nyt, er dagens bevægelse sølle

[Raun]

Men endelig lidt volumen.... - Det er jo lige før at hvad der er omsat den første time i dag - har været en hel dags omsætning den seneste tid...

[ProinvestorNEWS]

Genmab-rival skuffer med resultater i lungekræftstudie https://proinvestor.com/investornyt/1211578/genmab-rival-skuffer-med-resultater-i-lungekraeftstudie

[ProinvestorNEWS]

AstraZeneca :Dato-DXd Fails To Significantly Improve Overall Survival In Phase III Lung Cancer Trial https://proinvestor.com/investornyt/1211514/arrivent-announces-positive-phase-1b-data-for-firmonertinib-in-nsclc-with-egfr-pacc-mutations